Brenus Pharma Secures €11M Series A Extension, Attracting First Asia-Pacific Investor for Lead Immunotherapy STC-1010
Key Insights
Brenus Pharma (search) raised an €11 million ($12.6M) Series A extension, bringing total capital raised since inception to €38 million ($43.5M).
The funding will support completion of the Phase I program for STC-1010, an in-vivo immunotherapy targeting MSS metastatic colorectal cancer (NCT06934538).
Korea Omega Investment Corp (search) joined as the first Asia-Pacific institutional investor, alongside new European investor Sambrinvest (search).
Brenus Pharma (search), a Lyon-based immuno-oncology company, has announced an €11 million ($12.6M) extension to its Series A financing round, bringing total capital raised since inception to €38 million ($43.5M). The funding round attracted two new international investors — Sambrinvest (search) from Europe and Korea Omega Investment Corp (search), marking the company's first institutional investment from the Asia-Pacific region — alongside strong follow-on participation from existing backers.
The capital infusion reflects what the company describes as strong execution across clinical, regulatory, and business development milestones, particularly in de-risking STC-1010 (NCT06934538), its lead clinical-stage in-vivo immunotherapy for microsatellite stable metastatic colorectal cancer (search) (MSS mCRC).
Investor Confidence and International Expansion
The round saw continued support from existing investors including Angelor, UI Investissement (managing FRAI), Crédit Agricole (CACE Création, CACF Capital Innovation), Noshaq, Orsa (formerly Investsud), BIO JAG, and Bpifrance, the latter through non-dilutive funding.
Dae Kyeong Bae, Senior Vice President at Korea Omega Investment Corp (search), expressed strong conviction in the investment: "We couldn't be more confident in our first investment in France. The company combines truly differentiated technology with early clinical validation and team executing at pace. This is exactly the type of European innovation we want to support as we expand our portfolio internationally. We look forward to supporting Brenus as it advances its innovation toward a new treatment for patients with significant unmet medical needs."
Strategic Use of Proceeds
Paul Bravetti, CEO of Brenus Pharma (search), outlined the company's priorities for the new funding: "We are proud to welcome international investors who share our vision, and grateful for the continued confidence of our existing backers. This funding will enable us to complete the Phase I program and continue accelerating our in vivo immunotherapy platform by advancing our next drug candidate."
Platform Technology and Clinical Rationale
Brenus Pharma (search) is developing an off-the-shelf platform designed to advance novel modalities in immuno-oncology. The company's proprietary precision technology mimics tumor protein expression, rendering it visible to the immune system and enabling a multi-specific in vivo immune response. This approach is designed to adapt to tumor evolution in hard-to-treat solid tumors where current therapies have demonstrated limited efficacy.
STC-1010, the company's lead candidate currently in Phase I clinical trials under NCT06934538, targets MSS mCRC — a patient population with significant unmet medical need and historically limited response to existing immunotherapies. The successful completion of the Phase I program represents a critical near-term milestone for the company as it seeks to validate its platform approach and prepare for subsequent pipeline expansion.